Eli Lilly and Co

Eli Lilly was one of the largest relative contributors to the Portfolio’s performance in Q2 2026, indicating its positive impact on returns. However, the commentary does not provide specific reasons for holding or adding to the position, nor does it express a bullish or bearish view on the company. The focus is more on the overall market dynamics affecting various sectors, including healthcare, rather than a detailed analysis of Eli Lilly itself.

Eli Lilly is mentioned as one of the pharmaceutical producers contributing positively to the Thornburg Global Opportunities Fund portfolio performance during Q2’2026. However, there is no explicit directional argument made regarding its future performance or valuation.

Eli Lilly has outperformed Novo Nordisk, particularly due to its drug being marginally more effective and better marketed. The manager highlights that Novo's sales have started to fall, indicating real problems for the company. In contrast, Eli Lilly's performance suggests it is well-positioned in the market, especially as it competes effectively against its peers. The manager's confidence in Eli Lilly is reflected in their decision to increase their position in the company, viewing it as a strong investment opportunity.

Eli Lilly and Company, a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity, detracted from performance due to competitive pressures. However, we continue to view Lilly’s Mounjaro and Zepbound, along with its oral GLP-1 orforglipron, as best-in-class treatment options for diabetic and obese patients. We expect GLP-1 therapies to become the standard of care and to represent a $150-billion-plus market opportunity, reinforcing our positive long-term investment thesis.

Eli Lilly was mentioned as part of a strategic decision to trim exposure in some of the more expensive growth and higher-PE names. The manager noted that they strategically reduced their holdings in Eli Lilly among others, indicating a cautious approach rather than a strong bullish or bearish stance on the company itself.

Eli Lilly shares were a top performer in 4Q25 after delivering strong Q3 2025 earnings in October. Revenue rose 54% year-over-year to $17.6 billion, and adjusted EPS of $7.02 beat consensus of $6.02. Growth was driven by its GLP-1 franchises, Mounjaro and Zepbound, where sales more than doubled year-over-year, alongside strength in other therapeutic areas. This strong performance highlights the company's robust growth potential and competitive positioning in the pharmaceutical sector.

Eli Lilly shares were a top performer in 4Q25 after delivering strong Q3 2025 earnings in October. Revenue rose 54% year-over-year to $17.6 billion, and adjusted EPS of $7.02 beat consensus of $6.02. Growth was driven by its GLP-1 franchises, Mounjaro and Zepbound, where sales more than doubled year-over-year, alongside strength in other therapeutic areas.

Eli Lilly and Company is a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity. Shares declined after Phase 3 data for Lilly’s oral orforglipron in obesity fell short of elevated investor expectations. Investors had anticipated roughly 13% to 14% placebo-adjusted weight loss, while the trial showed 11.5%. The stock was also pressured by broader regulatory uncertainty related to potential sector tariffs and drug pricing risks. We view these risks as manageable and believe Lilly is among the least exposed pharmaceutical companies to both.

Eli Lilly And Co is the undisputed king of GLP-1 weight loss/diabetes drugs with Mounjaro and Zepbound, creating a multi-hundred-billion market. The Alzheimer’s drug donanemab adds a second blockbuster growth engine. Strong IP, manufacturing scale, and payer adoption build a moat. Risks—pricing pressure, competition (Novo Nordisk), and trial setbacks—are dwarfed by secular tailwinds in obesity and aging demographics. In short: Lilly is a generational growth story worth owning despite nosebleed valuation.

Eli Lilly delivered a standout quarter, with revenue increasing 54% YoY to $17.6B, driven by demand for its incretin portfolio – particularly Mounjaro and Zepbound. Mounjaro volume growth reached 60%, offsetting modest price declines. The company raised full-year guidance across revenue and EPS, reflecting sustained momentum. This performance underscores Eli Lilly's strong market position and growth potential in the health care sector.